Last reviewed · How we verify
Palbociclib administered Fasted
At a glance
| Generic name | Palbociclib administered Fasted |
|---|---|
| Sponsor | Pfizer |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- ER+/HER2- Locally Advanced or Metastatic Breast Cancer (ENZENO Study) (PHASE1, PHASE2)
- Drug Interaction Study To Investigate The Potential Effect Of Proton Pump Inhibitor On The Pharmacokinetics Of Palbociclib (PD-0332991) (PHASE1)
- A Pilot Study To Investigate The Effect Of Concurrent Antacid Administration On The Bioavailability Of Six Experimental Formulations Of Palbociclib (PHASE1)
- Characterization Of The Effect Of Food On Palbociclib (PD-0332991) Absorption (PHASE1)
- A Study In Healthy Volunteers To Estimate The Effect Of The Active Ingredient Particle Size And Percentage Of The Excipients Used To Formulate The Capsules In The Dissolution Rate Of The Formulations In The Gastrointestinal Tract (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Palbociclib administered Fasted CI brief — competitive landscape report
- Palbociclib administered Fasted updates RSS · CI watch RSS
- Pfizer portfolio CI